Upcoming Events
Iaso Therapeutics is attending the World Vaccine Conference in Washington, DC. Please visit our booth (Booth# S47) in the Start-Up area. You will be able to learn about Iaso’s technology, where you can buy mQβ for your vaccine research. Iaso seeks to speak with potential customers, identify potential strategic partners, and discuss the opportunity to invest in Iaso’s open financing round if you are a qualified investor.
R&D + Strategic Partnering For The Global Vaccine Industry
Mon April 3 2023, Pre-Congress Workshops
April 4 – 6 2023 – Main Congress Days
Walter E. Washington Convention Center
Iaso Therapeutics Announces First Close in $1.25M Equity Series Seed Preferred Financing
Iaso Therapeutics, a Michigan State University startup developing novel technologies for next-generation vaccines, recently closed the first tranche of the company’s $1.25M Series Seed Preferred round of financing.
Iaso Therapeutics Receives Grant from the National Science Foundation for Next-Generation Vaccine Research
The nearly $1 million grant will fund vaccine delivery research targeting infectious diseases and cancer EAST LANSING, Mich., March 14, 2022 -- Iaso Therapeutics, a research program focused on the [...]
Iaso Therapeutics Awarded Competitive Grant from the National Institute of Allergy and Infectious Diseases
Small Business Innovation Research Program Provides Seed Funding for R&D East Lansing, MI, 07/15/2021 – Iaso Therapeutics, INC. has been awarded a National Institute of Allergy and Infectious Diseases (NIAID) [...]
Building Better Vaccines: Iaso Therapeutics
Vaccines have dominated the news. With the COVID-19 pandemic, stories about vaccines have been a daily occurrence. They range from concerns about safety to vaccination rates and distribution. They [...]
Iaso Therapeutics secures investment from Michigan State University’s Student Venture Capital Fund
East Lansing, MI – Iaso has been selected to receive a $10k investment by the Michigan State University (MSU) Student Venture Capital Fund (MSU SVCF). This spring, Iaso participated in [...]
Iaso Therapeutics Invited to TRECS Workshop
East Lansing, MI – Iaso Therapeutics (Iaso) has received a selective invitation to participate in the National Cancer Institute (NCI) Translational Resources to Expedite Commercialization Success Workshop (TRECS WORKSHOP). Iaso [...]
‘An immense opportunity’: How LEAP wants Greater Lansing to become a med-tech hub
Craig Lyons Lansing State Journal LANSING – When Herbert Kavunja joined Iaso Therapeutics as its chief scientist and sole employee, he faced a steep learning curve. He had to figure [...]
Iaso Therapeutics Receives Phase I SBIR Grant from the National Cancer Institute
Iaso Therapeutics received a Phase I SBIR grant from the National Cancer Institute (NCI). The grant is to study the feasibility of developing a cancer vaccine against breast cancer including [...]
Iaso Therapeutics Receives Phase I SBIR Grant from the National Science Foundation
Iaso Therapeutics received a Phase I SBIR grant from the National Science Foundation (NSF). The grant is to study the feasibility of commercializing Iaso’s mutant Qβ (mQβ) virus-like particle. The [...]
